Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC lowered its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 17.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 72,667 shares of the life sciences company’s stock after selling 15,222 shares during the quarter. Wedge Capital Management L L P NC owned approximately 0.09% of Integra LifeSciences worth $1,320,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Blue Trust Inc. raised its stake in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the period. CWM LLC raised its stake in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares during the period. Valley National Advisers Inc. purchased a new position in shares of Integra LifeSciences in the 1st quarter valued at $63,000. Canada Pension Plan Investment Board purchased a new position in shares of Integra LifeSciences in the 2nd quarter valued at $114,000. Finally, Northwest Investment Counselors LLC purchased a new position in shares of Integra LifeSciences in the 1st quarter valued at $143,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of IART stock opened at $19.80 on Thursday. The firm has a market cap of $1.56 billion, a P/E ratio of 39.60, a P/E/G ratio of 0.62 and a beta of 1.09. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The firm has a fifty day moving average of $19.11 and a two-hundred day moving average of $25.71.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business had revenue of $418.20 million during the quarter, compared to analyst estimates of $413.07 million. During the same period in the previous year, the business posted $0.71 EPS. The company’s quarterly revenue was up 9.7% on a year-over-year basis. As a group, research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on IART shares. Citigroup cut their target price on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a research note on Tuesday, October 1st. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Morgan Stanley lifted their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. Bank of America dropped their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Finally, JMP Securities dropped their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $26.50.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.